KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Share-based Compensation (2016 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Share-based Compensation for 16 consecutive years, with $71.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Share-based Compensation fell 21.84% year-over-year to $71.6 million, compared with a TTM value of $348.2 million through Dec 2025, up 27.99%, and an annual FY2025 reading of $348.2 million, up 27.99% over the prior year.
  • Share-based Compensation was $71.6 million for Q4 2025 at Alnylam Pharmaceuticals, down from $108.2 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $128.1 million in Q3 2022 and bottomed at $29.3 million in Q1 2022.
  • Average Share-based Compensation over 5 years is $61.9 million, with a median of $50.7 million recorded in 2021.
  • The sharpest move saw Share-based Compensation surged 283.97% in 2022, then crashed 50.1% in 2023.
  • Year by year, Share-based Compensation stood at $44.6 million in 2021, then decreased by 4.07% to $42.8 million in 2022, then fell by 1.81% to $42.0 million in 2023, then surged by 118.23% to $91.6 million in 2024, then fell by 21.84% to $71.6 million in 2025.
  • Business Quant data shows Share-based Compensation for ALNY at $71.6 million in Q4 2025, $108.2 million in Q3 2025, and $111.7 million in Q2 2025.